Healthy subjects
Conditions
Interventions
Use test product for 3 days
Sponsors
Miura Clinic, Medical Corporation Kanonkai
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Subjects of men and women aged 20 to 40 (2) Subjects whose menstrual cycle is around 28 days (3)Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing
Exclusion criteria
Exclusion criteria: (1) Subjects with a history of diabetes, liver disease, renal disease, gastrointestinal disease, heart disease, respiratory disease, peripheral vascular disease, or other serious disease (2) Subjects with diseases currently being treated (3) Subjects with a history of gynecological disease (endometriosis, uterine fibroids, ovarian cysts, cervical cancer, uterine cancer, etc.) (4) Subjects with food and drug allergies (5) Female subjects who wish to become pregnant while participating in this study, female subjects who are pregnant (including those who may be pregnant) or who are breastfeeding (6) Subjects using products or drugs that affect hormone balance (7) Subjects receiving antibiotics (8) Subjects who participate in strenuous sports and who are on a diet (9)Subjects with irregular lifestyle (10) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (11) Subjects who are continuously receiving medical treatment (including OTC and prescription drugs) (12) Subjects who consume alcohol excessively (13) Subjects who cannot abstain from alcohol from the day before the test to the day of the test (14) Subjects participating in or planning to participate in other clinical trials at the start of this study (15) Subjects who are otherwise judged by the principal investigator or subinvestigator to be unsuitable for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| vaginal microbiota | — |
Countries
Japan
Contacts
Public ContactMakoto Terashima
Oneness Support Co., Ltd. Clinical Trial Division
Outcome results
None listed